Cytoprotective-selective activated protein C therapy for ischaemic stroke.

ABSTRACT: Despite years of research and efforts to translate stroke research to clinical therapy, ischaemic stroke remains a major cause of death, disability, and diminished quality of life. Primary and secondary preventive measures combined with improved quality of care have made significant progress. However, no novel drug for ischaemic stroke therapy has been approved in the past decade. Numerous studies have shown beneficial effects of activated protein C (APC) in rodent stroke models. In addition to its natural anticoagulant functions, APC conveys multiple direct cytoprotective effects on many different cell types that involve multiple receptors including protease activated receptor (PAR) 1, PAR3, and the endothelial protein C receptor (EPCR). Application of molecular engineered APC variants wi

SUBMITTER: Mosnier LO 

PROVIDER: S-EPMC4356129 | biostudies-literature | 2014 Nov

REPOSITORIES: biostudies-literature